2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phospholipase

Phospholipase

Phospholipase

Related Products

PDF 1.13 MB

Phospholipase is a member of a very complex group of enzymes that break down phospholipids into fatty acids and other compounds. Phospholipases are defined by the enzymatic reaction they catalyze. The classes are phospholipase A, which has members A1 and A2; phospholipase B, which can carry out the reactions of both A1 and A2; phospholipase C; and phospholipase D.

Phospholipase A2 (PLA2) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Phospholipase C (PLC) converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG and IP3 each control diverse cellular processes and are also substrates for synthesis of other important signaling molecules. PLC is thus central to many important interlocking regulatory networks. Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival.

Phospholipase Isoform Specific Products:

Phospholipase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N14103
    Cinatrin C1
    		Inhibitor
    Cinatrin C1 is a phospholipase A2 (PLA2) inhibitor that can be extracted from Circinotrichum falcatisporum RF-641.
    Cinatrin C1
  • HY-116273
    ML299
    		Inhibitor
    ML299 is a selective allosteric modulator and a dual inhibitor of phospholipases D1 and D2 (IC50 values are 6 and 12 nM, respectively). ML299 decreases invasive migration in U87-MG glioblastoma cells.
    ML299
  • HY-P10658
    ARF1 (2-17)
    		Inhibitor
    ARF1 (2-17) inhibits both ARF-independent (PLC-β) and ARF-dependent (PLD) pathways. ARF1 (2-17) inhibits GTP-γ-S-stimulated PLD activity, phospholipase C-β (PLC-β), and exocytosis.
    ARF1 (2-17)
  • HY-17569R
    Difluprednate (Standard)
    		Inhibitor
    Difluprednate (Standard) is the analytical standard of Difluprednate. This product is intended for research and analytical applications. Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
    Difluprednate (Standard)
  • HY-N14101
    Cinatrin B
    		Inhibitor
    Cinatrin B has the activity of inhibiting phospholipase A2.
    Cinatrin B
  • HY-115855
    Ro 31-4639
    		Inhibitor
    Ro 31-4639 is a potent phospholipase A2 inhibitor with an IC50 of 1.5 μM.
    Ro 31-4639
  • HY-127110
    AK106-001616
    		Inhibitor
    AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis.
    AK106-001616
  • HY-19151B
    Fuzapladib potassium
    		Inhibitor
    Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib potassium
  • HY-117068
    (R)-Bromoenol lactone
    		Inhibitor
    (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 µM.
    (R)-Bromoenol lactone
  • HY-B0113S4
    Omeprazole-d3 sodium
    		Inhibitor
    Omeprazole-d3 sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole-d<sub>3</sub> sodium
  • HY-131002A
    DPTIP hydrochloride
    		Inhibitor
    DPTIP hydrochloride is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC50 of 30 nM.
    DPTIP hydrochloride
  • HY-117068S
    (R)-Bromoenol lactone-d7
    		Inhibitor
    (R)-Bromoenol lactone-d7 ((R,E)-Bromoenol lactone-d7) is deuterium labeled (R)-Bromoenol lactone. (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 μM.
    (R)-Bromoenol lactone-d<sub>7</sub>
  • HY-158734
    Methyl γ-linolenyl fluorophosphonate
    		Inhibitor
    Methyl γ-linolenyl fluorophosphonate (MγLnFP) is a close analog of a well-characterized, irreversible inhibitor of phospholipases, methyl arachidonyl fluorophosphonate (MAFP).
    Methyl γ-linolenyl fluorophosphonate
  • HY-136994
    Sphingolactone-24
    		Inhibitor
    Sphingolactone-24 (Sph-24) is a selective and irreversible neutral sphingomyelinase (nSMase) inhibitor. Sphingolactone-24 has the potential for the research of acute lung injury.
    Sphingolactone-24
  • HY-120050
    GK470
    		Inhibitor
    GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels.
    GK470
  • HY-N7327
    Ochnaflavone
    		Inhibitor
    Ochnaflavone is an inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 of 3.45 µM. Ochnaflavone exhibits significant anti-inflammatory and liver-protective effects, capable of inhibiting the degradation of phosphatidylethanolamine (PE) and lipid peroxidation induced by carbon tetrachloride (CCl4) in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone can be used in research on liver damage and inflammatory diseases.
    Ochnaflavone
Cat. No. Product Name / Synonyms Application Reactivity
Phospholipase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.